Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. The company was founded based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute.
Synthorx’s expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins of any size, from small peptides to large biologics, and to manufacture these improved proteins at scale.
Synthorx’s unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies.
Synthorx is working internally and in collaboration with pharmaceutical companies toward the design and discovery of first-in- class drugs for a variety of therapeutic areas.
Synthorx’s investors include RA Capital Management, Avalon Ventures, and Correlation Ventures.